Disease · MONDO_0005885

optic neuritis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. optic neuritis. Diseases, record MONDO_0005885. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005885

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: optic neuritis; Open Targets
Open Targets ID: MONDO_0005885; Open Targets
Disease Ontology: DOID:1210; Disease Ontology
MeSH: D009902; MeSH
NCI Thesaurus: C84950; NCI Thesaurus
Highest stage of its drugs: Approval, for 4 of its 39 drugs, from DailyMed; Open Targets

Drugs39

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PREDNISONE	CHEMBL635	Small molecule	Approval	DailyMed	7	6	3	Drugs and targets
DEXAMETHASONE	CHEMBL384467	Small molecule	Approval	DailyMed	5	3	0	Drugs and targets
PREDNISOLONE	CHEMBL131	Small molecule	Approval	DailyMed	4	3	0	Drugs and targets
DEXAMETHASONE SODIUM PHOSPHATE	CHEMBL2021430	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
METHYLPREDNISOLONE	CHEMBL650	Small molecule	Phase 3	ClinicalTrials.gov	6	6	3	Drugs and targets
BETAMETHASONE	CHEMBL632	Small molecule	Phase 3	ClinicalTrials.gov	3	3	0	Drugs and targets
BETAMETHASONE SODIUM PHOSPHATE	CHEMBL1200762	Small molecule	Phase 3	ClinicalTrials.gov	3	3	0	Drugs and targets
HYDROCORTISONE	CHEMBL389621	Small molecule	Phase 3	ClinicalTrials.gov	3	3	0	Drugs and targets
TRIAMCINOLONE	CHEMBL1451	Small molecule	Phase 3	ClinicalTrials.gov	3	3	0	Drugs and targets
ECULIZUMAB	CHEMBL1201828	Antibody	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 39

See all 39 drugs

Targets75

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	10	Glucocorticoid receptor agonist	Approval	https://conductscience.org/library/genes/2908	Drugs and targets
CSF3R	Granulocyte colony-stimulating factor receptor	3	Granulocyte colony stimulating factor receptor agonist	Phase 1/2	https://conductscience.org/library/genes/1441	Drugs and targets
MS4A1	B-lymphocyte antigen CD20	2	B-lymphocyte antigen CD20 binding agent	Phase 3	https://conductscience.org/library/genes/931	Drugs and targets
VDR	Vitamin D3 receptor	2	Vitamin D receptor agonist	Phase 2	https://conductscience.org/library/genes/7421	Drugs and targets
C5	Complement C5	1	Complement C5 inhibitor	Phase 3	https://conductscience.org/library/genes/727	Drugs and targets
EPOR	Erythropoietin receptor	1	Erythropoietin receptor agonist	Phase 3	https://conductscience.org/library/genes/2057	Drugs and targets
FCGRT	IgG receptor FcRn large subunit p51	1	IgG receptor FcRn large subunit p51 antagonist	Phase 2	https://conductscience.org/library/genes/2217	Drugs and targets
HMGCR	3-hydroxy-3-methylglutaryl-coenzyme A reductase	1	HMG-CoA reductase inhibitor	Phase 3	https://conductscience.org/library/genes/3156	Drugs and targets
HRH1	Histamine H1 receptor	1	Histamine H1 receptor antagonist	Phase 2	https://conductscience.org/library/genes/3269	Drugs and targets
IFNAR1	Interferon alpha/beta receptor	1	Interferon alpha/beta receptor agonist	Phase 2/3	https://conductscience.org/library/genes/3454	Drugs and targets

1 to 10 of 75

See all 75 targets

Trials28

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 7 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01721161	BIIB033 In Acute Optic Neuritis (AON)	Phase 2	82	2016-06-30	Acute Optic Neuritis	OPICINUMAB	Its record names the disease	ClinicalTrials.gov
NCT02939937	Effect of Phenytoin on the Ganglion Cell Layer in Patients With Optic Neuritis	Phase 2	71	2019-08-12	Optic Neuritis	PHENYTOIN	Its record names the disease	ClinicalTrials.gov
NCT01337986	Ampyra for Optic Neuritis in Multiple Sclerosis	Phase 2/3	53	2020-01-30	Multiple Sclerosis, Optic Neuritis	DALFAMPRIDINE	Its record names the disease	ClinicalTrials.gov
NCT00856635	A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Function in Patients With a First Episode of Acute Optic Neuritis (AON). (Octagon)	Phase 3	44	2013-09-23	Optic Neuritis	GLATIRAMER ACETATE	Its record names the disease	ClinicalTrials.gov
NCT00624468	Atacicept in Subjects With Optic Neuritis	Phase 2	34	2016-02-17	Optic Neuritis	ATACICEPT	Its record names the disease	ClinicalTrials.gov
NCT00904826	An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica	Phase 1/2	14	2013-11-04	Neuromyelitis Optica, Devic's Disease	ECULIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00787722	Hematopoietic Stem Cell Transplant in Devic's Disease	Phase 1/2	13	2020-02-28	Devic's Disease	CYCLOPHOSPHAMIDE, RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT01759602	C1-esterase Inhibitor (Cinryze) for Acute Treatment of Neuromyelitis Optica Exacerbation	Phase 1	10	2014-07-18	Neuromyelitis Optica	CONESTAT ALFA	Its record names the disease	ClinicalTrials.gov
NCT01777412	Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations	Phase 1	10	2015-05-29	Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder	BEVACIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT02276963	Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses	Phase 1	6	2019-06-06	Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder	UBLITUXIMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 28

See all 28 trials

Comparisons in its trials6

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Dalfampridine vs Placebo: deaths from any cause	0 of 46	0 of 46	92	NCT01337986	Trial comparisons
Dalfampridine vs Placebo: serious adverse events	0 of 46	0 of 46	92	NCT01337986	Trial comparisons
BIIB033 100 mg/kg vs Placebo: serious adverse events	5 of 41	2 of 41	82	NCT01721161	Trial comparisons
Phenytoin vs Placebo: deaths from any cause	0 of 21	0 of 50	71	NCT02939937	Trial comparisons
Phenytoin vs Placebo: serious adverse events	1 of 21	0 of 50	71	NCT02939937	Trial comparisons
Glatiramer Acetate vs Placebo: serious adverse events	1 of 20	0 of 20	40	NCT00856635	Trial comparisons

Papers from its trials15

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
23623397	RESULT	1	PubMed
40997284	DERIVED	1	PubMed
35044445	DERIVED	1	PubMed
32126977	DERIVED	1	PubMed
30267385	DERIVED	1	PubMed
30095536	DERIVED	1	PubMed
29507942	DERIVED	1	PubMed
29172994	DERIVED	1	PubMed
28229892	DERIVED	1	PubMed
26822749	DERIVED	1	PubMed

1 to 10 of 15

See all 15 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005885

GET https://conductscience.org/api/diseases/v1/MONDO_0005885/drugs?page=2

API reference For AI assistants